Drug profile

The FDA adverse-event record for Pancreatic Enzymes

23 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Pancreatic Enzymes. Species, reactions, and outcomes follow.

#1664 of 2,679
by report volume (all drugs)
23
adverse-event reports
13.0%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Pancreatic Enzymes ranks #1638 of 2679 by total reports (23). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1638
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Pancreatic Enzymes has 23 reports now versus 23 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Pancreatic Enzymes changes

Signature read: report volume at 23 is the most distinctive stamp on Pancreatic Enzymes's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
23
Total Reports
3
Deaths Reported
13.0%
Death-coded share of reports

Active Ingredients

Pancreatic Enzymes

Administration Routes

UnknownOralOther

Species Affected

Dog 20
Cat 3

Most Affected Breeds

Shepherd Dog - German 5
Dog (other) 2
Retriever - Labrador 2
Bulldog - French 2
Domestic Longhair 2
Terrier - Jack Russell 1
Crossbred Canine/dog 1
Corgi (unspecified) 1
Sheepdog (unspecified) 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1

Most Reported Reactions

Lack of efficacy - NOS 5
Diarrhoea 3
Death by euthanasia 3
Walking difficulty 3
Seizure NOS 3
Pruritus 2
Panting 2
Vomiting 2
Pancreatitis NOS 2
Abscess NOS 2
Stroke 2
Wound 2

Outcome Breakdown

Recovered/Normal
7 (30.4%)
Ongoing
6 (26.1%)
Outcome Unknown
5 (21.7%)
Euthanized
3 (13.0%)
Recovered with Sequela
2 (8.7%)

Pancreatic Enzymes Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Pancreatic Enzymes (#1664 of 2,679 by report volume); death-coded 13.0%. PlainBreed drug row · report volume stamp 23 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →